These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 497698)

  • 1. Lupus-like autoimmune syndrome after levodopa and benserazide.
    Massarotti G; Cassi E; Passaleva A
    Br Med J; 1979 Sep; 2(6189):553. PubMed ID: 497698
    [No Abstract]   [Full Text] [Related]  

  • 2. ["Immune type" haemolysis in course of L. dopa-benserazide therapeutic (author's transl)].
    Conte P; Moulinier J; Reiffers J; Julien J
    Nouv Presse Med; 1979 Jan; 8(1):46-7. PubMed ID: 554063
    [No Abstract]   [Full Text] [Related]  

  • 3. Acute non-haemolytic anemia after short administration of L Dopa plus Benserazide.
    Pezzoli G; Passerini D; Scarlato G; Radaelli F
    Ann Allergy; 1982 Jun; 48(6):362. PubMed ID: 7091780
    [No Abstract]   [Full Text] [Related]  

  • 4. [Clinical significance of cramps of the lower extremities in patients with parkinsonism].
    Yu HZ
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1985 Aug; 18(4):217-8. PubMed ID: 4075911
    [No Abstract]   [Full Text] [Related]  

  • 5. Possible mechanism of adverse reaction following levodopa plus benserazide treatment.
    Messiha FS
    Br J Pharmacol; 1977 May; 60(1):55-7. PubMed ID: 884390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Long-term syndrome in the treatment of parkinsonism with L-dopa and decarboxylase an inhibitor].
    Chouza C; Romero S; Gomensoro JB
    Neurol Neurocir Psiquiatr; 1976; 17(4):255-68. PubMed ID: 828242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abnormal involuntary movements in relation to anticholinergics and levodopa therapy.
    Birket-Smith E
    Acta Neurol Scand; 1975 Aug; 52(2):158-60. PubMed ID: 1155032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-dose study of slow release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease.
    Marion MH; Stocchi F; Quinn NP; Jenner P; Marsden CD
    Adv Neurol; 1987; 45():493-6. PubMed ID: 3548262
    [No Abstract]   [Full Text] [Related]  

  • 9. Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia.
    Horstink MW; Zijlmans JC; Pasman JW; Berger HJ; van't Hof MA
    J Neurol Neurosurg Psychiatry; 1990 Mar; 53(3):224-6. PubMed ID: 2324754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Levodopa and decarboxylase inhibitors in Parkinson's disease].
    Gilland O
    Lakartidningen; 1977 Jan; 74(1-2):37-40. PubMed ID: 318722
    [No Abstract]   [Full Text] [Related]  

  • 11. Parkinson's disease in the elderly: a long-term efficacy study of levodopa/benserazide combination therapy.
    Mondal BK; Mondal KN
    Pharmatherapeutica; 1986; 4(9):571-6. PubMed ID: 3094036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levodopa/Benserazide-Induced Drug Reaction With Eosinophilia and Systemic Symptom Syndrome.
    Ben Salem C; Slim R; Fathallah N; Ghariani N; Sriha B; Denguezli M
    Dermatitis; 2023; 34(3):269-270. PubMed ID: 35089903
    [No Abstract]   [Full Text] [Related]  

  • 13. Hydrazine derivatives and induction of systemic lupus erythematosus.
    Pereyo N
    J Am Acad Dermatol; 1986 Mar; 14(3):514-5. PubMed ID: 3958266
    [No Abstract]   [Full Text] [Related]  

  • 14. Benserazide induces migraine attacks. Irrelevance of concomitant hyperprolactinemia.
    Polleri A; Murialdo G; Martignoni E; Nappi G; Savoldi F
    Farmaco Sci; 1979 May; 34(5):465-8. PubMed ID: 554794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of the effects of controlled-release levodopa (Madopar CR) with conventional levodopa in late Parkinson's disease.
    MacMahon DG; Sachdev D; Boddie HG; Ellis CJ; Kendal BR; Blackburn NA
    J Neurol Neurosurg Psychiatry; 1990 Mar; 53(3):220-3. PubMed ID: 2182781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydrazine and lupus.
    Durant PJ; Harris RA
    N Engl J Med; 1980 Sep; 303(10):584-5. PubMed ID: 7402226
    [No Abstract]   [Full Text] [Related]  

  • 17. [Presentation of a case of Graves' disease with neutropenia and splenomegaly: propylthiouracil-induced autoimmune neutropenia and review of the literature on the drug-induced lupus-like syndrome].
    Miyakawa M; Sato K; Sato Y; Tsushima T; Shizume K; Inoue T
    Nihon Naika Gakkai Zasshi; 1984 Apr; 73(4):538-45. PubMed ID: 6547974
    [No Abstract]   [Full Text] [Related]  

  • 18. Bromocriptine alone or associated with L-dopa plus benserazide in Parkinson's disease.
    Caraceni TA; Celano I; Parati E; Girotti F
    J Neurol Neurosurg Psychiatry; 1977 Dec; 40(12):1142-6. PubMed ID: 591982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Combined treatment of the early stages of Parkinson's syndrome with bromocriptine and levodopa. The results of a multicenter study].
    Fischer PA; Przuntek H; Majer M; Welzel D
    Dtsch Med Wochenschr; 1984 Aug; 109(34):1279-83. PubMed ID: 6381019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Lymphocytic colitis due to Modopar].
    Rassiat E; Michiels C; Sgro C; Yaziji N; Piard F; Faivre J
    Gastroenterol Clin Biol; 2000; 24(8-9):852-3. PubMed ID: 11011265
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.